Does atrial fibrillation impact survival in patients with wild-type transthyretin cardiac amyloidosis?
Atrial fibrillation in wild-type transthyretin cardiac amyloidosis does not negatively impact patient survival.
These data provide an evidence basis for clinical management and demonstrate that AF in ATTRwt does not negatively impact survival. Further analysis of the relationship between transthyretin concentration and AF development is warranted.
Mints et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: